MedPath

Dexamethasone

Generic Name
Dexamethasone
Brand Names
Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
Drug Type
Small Molecule
Chemical Formula
C22H29FO5
CAS Number
50-02-2
Unique Ingredient Identifier
7S5I7G3JQL
Background

Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication

Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions
Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
Associated Therapies
-

Treatment of High Risk Adult Acute Lymphoblastic Leukemia

Phase 4
Completed
Conditions
Acute Lymphoblastic Leukemia
First Posted Date
2009-02-27
Last Posted Date
2020-04-07
Lead Sponsor
PETHEMA Foundation
Target Recruit Count
100
Registration Number
NCT00853008
Locations
🇪🇸

Hospital Germans Trias i Pujol, Badalona, Spain

🇪🇸

Clínica Teknon, Barcelona, Spain

🇪🇸

Hospital de Fuenlabrada, Madrid, Spain

and more 30 locations

Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma

Phase 1
Terminated
Conditions
Refractory Multiple Myeloma
Stage I Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma
Interventions
First Posted Date
2009-02-23
Last Posted Date
2017-09-08
Lead Sponsor
University of Washington
Target Recruit Count
31
Registration Number
NCT00849251
Locations
🇺🇸

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma

Phase 2
Terminated
Conditions
Multiple Myeloma
Interventions
First Posted Date
2009-02-13
Last Posted Date
2017-07-19
Lead Sponsor
NYU Langone Health
Target Recruit Count
8
Registration Number
NCT00843310
Locations
🇺🇸

Bellevue Hospital, New York, New York, United States

🇺🇸

NYU Tisch Hospital, New York, New York, United States

🇺🇸

NYU Cancer Center, New York, New York, United States

Oral Aprepitant and Lower Dose Dexamethasone Versus Aprepitant Alone for Preventing Postoperative Nausea and Vomiting (PONV) After Elective Laparoscopic Surgeries

Not Applicable
Conditions
Nausea
Vomiting
Interventions
First Posted Date
2009-02-04
Last Posted Date
2009-02-04
Lead Sponsor
Main Line Health
Target Recruit Count
50
Registration Number
NCT00835965
Locations
🇺🇸

Lankenau Hospital, Wynnewood, Pennsylvania, United States

MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma

Phase 1
Completed
Conditions
Multiple Myeloma
Interventions
First Posted Date
2009-02-02
Last Posted Date
2016-04-27
Lead Sponsor
Celgene Corporation
Target Recruit Count
259
Registration Number
NCT00833833
Locations
🇺🇸

Colorado Blood Cancer Institute, Denver, Colorado, United States

🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

🇺🇸

Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

and more 16 locations

A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy

Phase 2
Completed
Conditions
Multiple Myeloma
Interventions
First Posted Date
2009-02-02
Last Posted Date
2014-11-21
Lead Sponsor
Janssen-Cilag G.m.b.H
Target Recruit Count
401
Registration Number
NCT00833560

Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores

Phase 2
Terminated
Conditions
Breast Neoplasms
Breast Cancer
Cancer of the Breast
Interventions
First Posted Date
2009-01-30
Last Posted Date
2017-08-31
Lead Sponsor
Emory University
Target Recruit Count
23
Registration Number
NCT00832338
Locations
🇺🇸

Emory University Hospital Midtown, Atlanta, Georgia, United States

🇺🇸

Grady Memorial Hospital, Atlanta, Georgia, United States

🇺🇸

Emory University Winship Cancer Institute, Atlanta, Georgia, United States

Dexamethasone for Postoperative Nausea and Vomiting

Phase 4
Completed
Conditions
Postoperative Nausea and Vomiting
Interventions
First Posted Date
2009-01-19
Last Posted Date
2016-05-13
Lead Sponsor
University of Jordan
Target Recruit Count
180
Registration Number
NCT00825071
Locations
🇯🇴

Jordan University Hospital, Amman, Jordan

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)

Phase 1
Terminated
Conditions
Chemotherapy-Induced Nausea and Vomiting
Interventions
First Posted Date
2009-01-07
Last Posted Date
2018-09-25
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
92
Registration Number
NCT00818259

Tumor Gene Expression in Women With Ovarian Cancer

Phase 4
Completed
Conditions
Ovarian Cancer
Interventions
Drug: Placebo
Drug: Dexamethasone
First Posted Date
2009-01-06
Last Posted Date
2016-07-13
Lead Sponsor
University of Chicago
Target Recruit Count
20
Registration Number
NCT00817479
Locations
🇺🇸

The University of Chicago, Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath